What Health Canada Now Expects in a Class III or IV Medical Device Licence Application

If you sell a moderate or high risk medical device in Canada, the single document that most affects your next filing is short, plain, and easy to miss. On 16 July 2026, Health Canada issued a notice to industry on the expectations for information submitted with Class III and IV medical device licence applications. It does not add a new form or a new fee. It changes something more fundamental: what a well prepared dossier looks like, and what the Medical Devices Directorate will treat as a delay rather than as diligence. This is Health Canada content about what goes inside a Canadian licence application. It is not the United States regime. If you are working an FDA submission, our companion piece on the FDA PMA eSTAR electronic submission covers that side of the border.

For years, the instinct of many applicants was to file everything. Every report, every appendix, every version of every study, on the theory that more is safer. Health Canada has now said the opposite. Reviewers are seeing dossiers so large that finding the evidence takes longer than assessing it, and that padding is being counted against the applicant, not for them. This article explains what a Class III or IV application must contain under the Medical Devices Regulations, what the July 2026 notice expects on top of that, where applications actually fail, and how to file so the decision comes back on the first pass instead of six months later.

What the 16 July 2026 notice actually says

The notice is a signal about submission quality, not a new legal requirement. Health Canada observed a significant increase in the volume of information filed with Class III and IV applications and warned that unnecessary or duplicative content delays review. The expectation now: submit only what supports the application, provide clear and concise summaries that accurately reflect the data, and clearly identify what is needed for a timely review.

Read carefully, the notice does three things. First, it reframes volume as a risk rather than a virtue. A 4,000 page dossier where the pivotal evidence sits in an unmarked appendix is now a slower dossier, because the reviewer has to hunt for the studies that actually support safety and effectiveness. Second, it reinforces an existing legal requirement that many applicants treat as optional: applications for Class III and IV licences must include summaries of the studies and evidence submitted, and those summaries must be accurate. Third, it puts the applicant squarely on the hook for anything produced by an artificial intelligence tool. If you use AI to draft a summary or an explanatory section, you own its accuracy and its fidelity to the underlying data.

The table below sets out the shift in plain terms.

What a Class III or IV licence application must contain

Under the Medical Devices Regulations (SOR/98-282), a manufacturer of a Class II, III or IV device must hold a medical device licence before importing or selling it in Canada. Section 32 sets out what a licence application must contain, and the requirements deepen with the class. A Class III or IV application must include the device description and intended use, a list of the standards used to meet safety and effectiveness requirements, a summary of the studies and the conclusions drawn, and, for Class IV, the most detailed evidence of safety and effectiveness. Every Class III and IV application must also carry a valid ISO 13485 quality management system certificate issued through the Medical Device Single Audit Program.

The distinction between the two classes drives how much evidence you need and how deeply it is scrutinized. Class III covers moderate to high risk devices. Class IV covers the highest risk devices, those most often life sustaining or implantable. The comparison below is a working orientation, not a substitute for confirming your device's class against the classification rules in the Regulations.

Screening versus review: where applications actually die

Most applicants think the risk is a negative scientific decision at the end of review. In practice, the most common and most avoidable failures happen at the start, during screening. Health Canada's guidance on managing applications for medical device licences (version 5, effective 2 February 2026) sets out two distinct gates: a screening step that checks the application is complete and correctly assembled, and a review step that assesses the evidence. An application that fails screening never reaches a reviewer.

At screening, Health Canada confirms the application is filed through the Regulatory Enrolment Process, that the correct fee status is set, that the required elements of section 32 are present, and that the summaries and evidence can be located. If something is missing or unclear, you receive a screening deficiency letter or a clarification request, and the application waits on your response. If the screening deficiency is not resolved in the time stated, the application can be withdrawn and you start again, including the fee. This is exactly the terrain the July 2026 notice targets. An over-stuffed dossier makes screening slower and clarification requests more likely, because the screener cannot quickly confirm that the required summaries are present and consistent with the data.

The five most common screening and review deficiencies

Across Class III and IV filings, the same handful of problems keep resetting the clock. Each one is preventable before you submit, and each maps to a corrective action you can build into your pre-submission process.

1. Missing or inaccurate evidence summaries. The Regulations require summaries of the studies and evidence, and the notice requires those summaries to accurately reflect the data. A summary that overstates a result, omits a failed endpoint, or points to the wrong appendix invites a clarification request at best and undermines credibility at worst. Corrective action: have a second qualified reviewer reconcile every summary line against the source study before filing.

2. Volume without navigation. A large dossier with no clear map of where the pivotal evidence sits is now a self-inflicted delay. Corrective action: right-size the submission to what supports the application, and give each section a short index that tells the reviewer exactly where the safety and effectiveness evidence is.

3. An expired, mismatched, or wrong-scope ISO 13485 certificate. A quality management system certificate that has lapsed, that names a different manufacturer, or that does not cover the device in the application is a frequent screen-out. Corrective action: confirm the certificate is current, issued under MDSAP, in the correct legal manufacturer name, and covers the device before you file.

4. Standards and conformity gaps. Relying on a standard that has been superseded, or claiming conformity without the supporting test evidence, produces an Additional Information Request. Corrective action: check each standard against Health Canada's recognized standards list and hold the underlying reports ready to file.

5. Unchecked AI-generated content. A summary drafted by an AI tool that misstates a figure or invents a citation is now explicitly the applicant's responsibility. Corrective action: treat AI output as a first draft only, and record human verification of every AI-assisted section as part of your document control.

Additional Information Requests and the response protocol

An Additional Information Request under section 35 is issued when the information filed is insufficient for Health Canada to decide whether the device meets the safety and effectiveness requirements. It is not a rejection. It is a deadline. You must provide the information by the day specified, and if you do not, section 38 allows Health Canada to refuse the licence. A refusal comes with written reasons and an opportunity to be heard, but by then you have lost months.

Treat every AIR as a project with a single owner, a logged due date, and a controlled response package. Answer the question that was asked, provide the specific evidence requested, and add a short cover summary that maps your response to each point in the request. Do not use an AIR response to dump additional volume, that repeats the very problem the July 2026 notice was written to solve. If you cannot meet the deadline, engage Health Canada before it passes rather than after.

Right-sizing the dossier and governing AI-generated summaries

Right-sizing does not mean filing less evidence. It means filing the evidence that supports the application, presented so a reviewer can find and follow it. Everything that meets a requirement belongs in the dossier. Everything that is duplicative, tangential, or unexplained is a delay. The discipline is editorial as much as scientific: a clear index, consistent summaries, and a direct line from each claim to its supporting study.

On artificial intelligence, the notice is a governance prompt, not a prohibition. You may use AI tools to help draft summaries or explanatory material, but you are accountable for the result. Build a simple control: any AI-assisted section is verified by a named, qualified person against the source data, and that verification is recorded. This mirrors the human oversight expectation that regulators, including the FDA, have begun to enforce for AI-generated quality documentation.

Class III and IV filing readiness checklist

Run this before any Class III or IV licence application leaves your regulatory desk.

• Device class confirmed against the classification rules in SOR/98-282, and the correct application type selected.
• Application filed through the Regulatory Enrolment Process with the correct fee status set.
• Evidence summaries present, clear, and reconciled line by line against the source studies.
• Dossier right-sized to what supports the application, with a section index pointing to the pivotal evidence.
• ISO 13485 certificate current, issued under MDSAP, in the correct manufacturer name, and covering the device.
• Every standard checked against Health Canada's recognized standards list, with supporting test reports on hand.
• Any AI-assisted text verified by a named qualified reviewer, with the verification recorded.
• A single named owner and a standing process ready to handle any screening deficiency or Additional Information Request against its deadline.

Common mistakes to avoid

• Filing everything on file in the belief that volume protects you. It now slows you down.
• Writing summaries after the dossier is assembled, so they drift out of step with the evidence.
• Treating an Additional Information Request as optional or open-ended. The deadline is real and refusal follows a missed one.
• Assuming a foreign approval carries your Canadian file. Recognized foreign evidence can help, but the Canadian requirements still govern.
• Submitting AI-generated summaries without human verification, and owning the error when a figure is wrong.

Frequently asked questions

What is the difference between a Class III and a Class IV device in Canada?

Both are higher risk classes that require a medical device licence before import or sale. Class III covers moderate to high risk devices, and Class IV covers the highest risk devices, often life sustaining or implantable. Class IV applications carry the deepest safety and effectiveness evidence. Your device's class is set by the classification rules in the Medical Devices Regulations, not by choice.

Does the July 2026 notice mean I should file less evidence?

No. It means file the right evidence, well summarized and easy to find. Everything that supports the application belongs in the dossier. What Health Canada is discouraging is unnecessary or duplicative material and summaries that do not match the data. Right-sizing is about clarity and traceability, not about withholding evidence.

What is an Additional Information Request?

It is a request under section 35 of the Regulations for information Health Canada needs to decide whether your device meets the safety and effectiveness requirements. You must respond by the day specified. If you do not, section 38 allows Health Canada to refuse the licence. An AIR is a deadline to manage, not a rejection.

Do I need MDSAP certification to apply?

A Class III or IV application must include a valid ISO 13485 quality management system certificate, and Health Canada recognizes certificates issued through the Medical Device Single Audit Program. Confirm the certificate is current, in the correct manufacturer name, and covers the device in your application before you file.

Why was my medical device licence application screened out?

Screen-outs usually come from completeness and assembly problems rather than science: a missing or inconsistent summary, an expired or mismatched quality certificate, the wrong fee status, or a dossier so large the required elements cannot be confirmed. Resolve the deficiency within the stated time or the application can be withdrawn and you refile.

Can I use AI to write my application summaries?

Yes, but you are responsible for the accuracy of the result. Health Canada's notice states that applicants who use AI tools to generate summaries or explanatory material must ensure the content is accurate and reflects the supporting data. Build a control that records human verification of every AI-assisted section.

How MFLRC can help

MF License and Regulatory Consultants prepares and reviews Class III and IV medical device licence applications for Canadian and foreign manufacturers. A short pre-submission dossier review costs a fraction of a six-month Additional Information Request cycle, and it is the highest-leverage step you can take before filing. We reconcile your evidence summaries against the source studies, right-size the dossier so the pivotal evidence is easy to find, confirm your ISO 13485 quality management system certification is in order, and check every standard against Health Canada's recognized list. We also support MDEL holders and importers, including firms working through the new MDEL rules in force in December 2026.

Our services include pre-submission dossier review and evidence gap analysis, Class III and IV application preparation, Additional Information Request response drafting, MDSAP and ISO 13485 readiness, recognized standards impact assessment, quality management system builds, and standard operating procedures for your regulatory intake process. If you are deciding whether to file in-house or engage support, a filing readiness assessment gives you a clear answer before you commit the fee.

Conclusion

The 16 July 2026 notice is short, but it resets the standard for a Class III or IV filing in Canada. The best applications are no longer the biggest. They are the ones that give a reviewer exactly what is needed, summarized accurately, easy to navigate, and backed by a current quality system. Whether you are filing a first device, upgrading a class, or preparing a machine learning enabled device, the discipline is the same: file for the first-pass decision, and treat every screening deficiency and information request as a deadline you own.

Sources and references

• Health Canada, Expectations for information submitted with Class III and IV medical device licence applications: Notice to industry (16 July 2026)
• Medical Devices Regulations (SOR/98-282), Justice Laws Website
• Health Canada, Guidance on managing applications for medical device licences (version 5, effective 2 February 2026)
• Health Canada, Medical devices overview
• ISO 13485:2016, Medical devices, Quality management systems, Requirements for regulatory purposes